Details for New Drug Application (NDA): 018685
✉ Email this page to a colleague
NDA 018685 describes GAVISCON, which is a drug marketed by Chattem Sanofi and is included in one NDA. Additional details are available on the GAVISCON profile page.
The generic ingredient in GAVISCON is aluminum hydroxide; magnesium trisilicate. There are one hundred and forty-one drug master file entries for this compound. Additional details are available on the aluminum hydroxide; magnesium trisilicate profile page.
The generic ingredient in GAVISCON is aluminum hydroxide; magnesium trisilicate. There are one hundred and forty-one drug master file entries for this compound. Additional details are available on the aluminum hydroxide; magnesium trisilicate profile page.
Summary for 018685
| Tradename: | GAVISCON |
| Applicant: | Chattem Sanofi |
| Ingredient: | aluminum hydroxide; magnesium trisilicate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, CHEWABLE;ORAL | Strength | 80MG;20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 9, 1983 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, CHEWABLE;ORAL | Strength | 160MG;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 9, 1983 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
